04 Feb. 2026
Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP) 
08 Jan. 2026
Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
24 Dec. 2025
Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate
23 Sep. 2025
Foresee Pharmaceuticals Announce syMMPonia Abstract Presentation at European Respiratory Society (ERS) Congress
29 Aug. 2025
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
17 Jun. 2025
